Autopsy report · NCT02154529

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

“Sponsor closed the study due to lack of response.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 6 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Kadmon Corporation, LLC

Sponsor type

Industry

Conditions

HER-2 Positive Breast Cancer; Metastatic Malignant Neoplasm to Brain

Interventions

Tesevatinib; Trastuzumab

Participants

17

Sites

6

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.